{"id":"estradiol-valerate-dienogest","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nausea"},{"rate":"5-20","effect":"Headache"},{"rate":"5-15","effect":"Breast tenderness"},{"rate":"5-20","effect":"Breakthrough bleeding"},{"rate":"5-10","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"}]},"_chembl":null,"_dailymed":{"setId":"3fbcd7d8-cc53-4dbb-8edc-451acadc472c","title":"NATAZIA (ESTRADIOL VALERATE AND ESTRADIOL VALERATE/DIENOGEST) KIT [PHYSICIANS TOTAL CARE, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Estradiol valerate is an estrogen that provides estrogenic activity, while dienogest is a progestin that suppresses the luteinizing hormone (LH) surge necessary for ovulation. Together, they create a hormonal environment that prevents follicle development and ovulation, and also thickens cervical mucus to impede sperm penetration. This combination is used in oral contraceptive formulations.","oneSentence":"Estradiol valerate and dienogest work together as a hormonal contraceptive by suppressing ovulation through progestin and estrogen activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:43.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception"},{"name":"Regulation of menstrual cycle"}]},"trialDetails":[{"nctId":"NCT07204093","phase":"","title":"Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2025-08-11","conditions":"Endometriosis","enrollment":138},{"nctId":"NCT06396208","phase":"NA","title":"\"Quick-starting\" of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2024-05-01","conditions":"Ultrasound Finding: Ovulation Inhibition, Ovarian Activities, Cervical Mucus, Serum Hormonal Profile","enrollment":40},{"nctId":"NCT02636972","phase":"","title":"The Progression From Dysmenorrhoea to Chronic Pelvic Pain","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2014-11","conditions":"Dysmenorrhoea, Pelvic Pain, Chronic Pain","enrollment":56},{"nctId":"NCT06145438","phase":"PHASE3","title":"Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery","status":"COMPLETED","sponsor":"Universitas Diponegoro","startDate":"2023-09-04","conditions":"Endometriosis Ovary","enrollment":80},{"nctId":"NCT00754065","phase":"PHASE3","title":"To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-09-08","conditions":"Contraception","enrollment":409},{"nctId":"NCT03751800","phase":"","title":"A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-12-12","conditions":"Menorrhagia","enrollment":422},{"nctId":"NCT06577974","phase":"NA","title":"Role of Medical Treatment in Endometriosis Patients Undergoing ICSI","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-07-01","conditions":"Endometriosis","enrollment":129},{"nctId":"NCT02400801","phase":"NA","title":"Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-06","conditions":"Endometriosis, Infertility","enrollment":166},{"nctId":"NCT06316206","phase":"PHASE4","title":"The Use of Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2023-01-01","conditions":"Endometrial Polyp, Endometrial Diseases","enrollment":80},{"nctId":"NCT06324851","phase":"PHASE4","title":"The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2023-01-01","conditions":"Endometrial Polyp, Endometrial Diseases","enrollment":150},{"nctId":"NCT03945513","phase":"PHASE3","title":"A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles","status":"COMPLETED","sponsor":"Insud Pharma","startDate":"2019-12-03","conditions":"Contraception","enrollment":1034},{"nctId":"NCT04901377","phase":"","title":"A Study to Gather Information About User Satisfaction in Women in Russia Who Take Estradiol Valerate/Dienogest","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-06-24","conditions":"Oral Contraception","enrollment":255},{"nctId":"NCT02352090","phase":"PHASE4","title":"Synthetic vs Natural Estrogen in Combined Oral Contraception","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2015-04-01","conditions":"Contraception","enrollment":59},{"nctId":"NCT05332106","phase":"PHASE1","title":"Bioavailability of Estradiol Valerate and Dienogest 2 mg/2 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2022-03-12","conditions":"Bioequivalence","enrollment":10},{"nctId":"NCT04256200","phase":"PHASE2, PHASE3","title":"Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis","status":"UNKNOWN","sponsor":"American University of Beirut Medical Center","startDate":"2017-02-07","conditions":"Endometriosis","enrollment":100},{"nctId":"NCT03890042","phase":"NA","title":"Dienogest for Treatment of Adenomyotic Uteri","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-03-01","conditions":"Adenomyosis","enrollment":100},{"nctId":"NCT03353857","phase":"PHASE1","title":"Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-11-29","conditions":"Biological Availability","enrollment":68},{"nctId":"NCT01600274","phase":"NA","title":"Bioavailability Study With Oral Single Dose Administration of Ethinylestradiol and Dienogest","status":"COMPLETED","sponsor":"Pharbil Waltrop GmbH","startDate":"2010-01","conditions":"Focus: Bioequivalence","enrollment":20},{"nctId":"NCT04193852","phase":"PHASE1","title":"Bioavailability of Dienogest and Ethinyl Estradiol Tablets 2.0 mg/0.03 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2019-11-09","conditions":"Bioequivalence","enrollment":10},{"nctId":"NCT01009684","phase":"","title":"International Active Surveillance Study - Safety of Contraceptives: Role of Estrogens","status":"COMPLETED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2009-08","conditions":"Contraception","enrollment":50203},{"nctId":"NCT01602770","phase":"","title":"Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-02-06","conditions":"Contraception","enrollment":1},{"nctId":"NCT03172533","phase":"PHASE2","title":"Estrogen Replacement in Anorexia Nervosa","status":"TERMINATED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2016-03-15","conditions":"Anorexia Nervosa","enrollment":11},{"nctId":"NCT03789123","phase":"PHASE4","title":"Effects of Dienogest and Dienogest Plus Estradiol Valerate in Ovarian Endometrioma","status":"UNKNOWN","sponsor":"Bagcilar Training and Research Hospital","startDate":"2019-01-01","conditions":"Ovarian Reserve","enrollment":710},{"nctId":"NCT03124524","phase":"PHASE4","title":"Treatment Choice in Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Adana Numune Training and Research Hospital","startDate":"2015-01-15","conditions":"Primary Dysmenorrhea","enrollment":99},{"nctId":"NCT02599077","phase":"PHASE2, PHASE3","title":"Impact vs. Dienogest: A Combined Oral Contraceptive in the Size of Endometriomas","status":"SUSPENDED","sponsor":"Fundación Santa Fe de Bogota","startDate":"2015-11","conditions":"Endometriosis","enrollment":50},{"nctId":"NCT00941057","phase":"PHASE1","title":"Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-09","conditions":"Pharmacology, Clinical","enrollment":43},{"nctId":"NCT00778609","phase":"PHASE3","title":"Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Oral Contraceptive, Headache, Pelvic Pain","enrollment":449},{"nctId":"NCT00909857","phase":"PHASE3","title":"Effect on Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-04","conditions":"Primary Dysmenorrhea","enrollment":507},{"nctId":"NCT01638923","phase":"PHASE3","title":"Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-06","conditions":"Metrorrhagia","enrollment":339},{"nctId":"NCT02385448","phase":"PHASE4","title":"Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2015-02","conditions":"Endometriosis","enrollment":144},{"nctId":"NCT00307801","phase":"PHASE3","title":"Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-02","conditions":"Metrorrhagia","enrollment":231},{"nctId":"NCT00335218","phase":"PHASE4","title":"Fat Distribution in Healthy Early Postmenopausal Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-07","conditions":"Healthy, Postmenopause","enrollment":67},{"nctId":"NCT00764881","phase":"PHASE3","title":"Effects of SH T00658ID on Libido","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-01","conditions":"Contraception, Libido","enrollment":217},{"nctId":"NCT01638910","phase":"PHASE3","title":"Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-06","conditions":"Contraception","enrollment":955},{"nctId":"NCT00293059","phase":"PHASE3","title":"Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-12","conditions":"Metrorrhagia","enrollment":190},{"nctId":"NCT00471991","phase":"PHASE2","title":"Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-04","conditions":"Oral Contraceptive","enrollment":60},{"nctId":"NCT01221831","phase":"PHASE2","title":"Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2","status":"COMPLETED","sponsor":"Estetra","startDate":"2010-09","conditions":"Contraception","enrollment":396},{"nctId":"NCT00805415","phase":"PHASE2","title":"Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-03","conditions":"Ovulation Inhibition","enrollment":209}],"_emaApprovals":[],"_faersSignals":[{"count":19,"reaction":"PREGNANCY ON ORAL CONTRACEPTIVE"},{"count":13,"reaction":"HEADACHE"},{"count":13,"reaction":"METRORRHAGIA"},{"count":10,"reaction":"AMENORRHOEA"},{"count":9,"reaction":"ABORTION SPONTANEOUS"},{"count":8,"reaction":"HYPERSENSITIVITY"},{"count":8,"reaction":"VAGINAL HAEMORRHAGE"},{"count":7,"reaction":"ASTHENIA"},{"count":7,"reaction":"PRURITUS"},{"count":7,"reaction":"VOMITING"}],"_approvalHistory":[{"date":"20100506","type":"ORIG","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA022252"},{"date":"20150821","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA022252"},{"date":"20120314","type":"ORIG","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA022252"},{"date":"20240626","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA022252"},{"date":"20220429","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA022252"},{"date":"20130822","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA022252"},{"date":"20120213","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA022252"}],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Qlaira, ATC code G03AB08"],"phase":"marketed","status":"active","brandName":"Estradiol valerate / dienogest","genericName":"Estradiol valerate / dienogest","companyName":"Helsinki University Central Hospital","companyId":"helsinki-university-central-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Estradiol valerate and dienogest work together as a hormonal contraceptive by suppressing ovulation through progestin and estrogen activity. Used for Contraception, Regulation of menstrual cycle.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}